BTIG Maintains Buy on Genmab, Raises Price Target to $46
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Kaveri Pohlman maintains a Buy rating on Genmab (NASDAQ:GMAB) and raises the price target from $44 to $46.
October 13, 2023 | 3:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BTIG analyst maintains a Buy rating on Genmab and raises the price target from $44 to $46, indicating positive sentiment towards the stock.
The raised price target by BTIG analyst indicates a positive outlook for Genmab. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100